Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women.
نویسندگان
چکیده
OBJECTIVE The aim of this study was to evaluate the levels of adipose tissue related hormones, cytokines, and antioxidative substances in obese women before and after intervention with diet alone or with diet plus an inhibitor of gastrointestinental lipase-orlistat. DESIGN Seventy-one obese women of childbearing age were included in the study and were randomly assigned into two groups according to the type of intervention: group A1 (n=35) included women who received orlistat as well as a hypocaloric diet, and group A2 (n=36) included women who were only on hypocaloric diet. The intervention period lasted 6 months. Anthropometric parameters, such as Body Weight (BW), Body Mass Index (BMI), Waist Circumference (WC), and %Body fat (BF) were recorded. Insulin, leptin, resistin, interleukin-6 (IL-6), insulin like growth factor 1 (IGF-1), tumor necrosis factor alpha (TNFalpha), adiponectin, hsC-reactive protein (CRP), glutathione peroxidase, and isoprostane were determined by appropriate methodology prior to and following the 6-month intervention period. Insulin resistance was measured using the homeostasis model assessment index (HOMA-IR). All participants had normal glucose tolerance. RESULTS In both groups B MI values were lower after intervention and all measured parameters were ameliorated. A statistically significant difference was found between group A1 (orlistat plus diet) and group A2 (diet only) with regard to the levels of triglycerides, CRP, TNF-alpha, IGF-1, and isoprostane, even after correcting for weight loss. CONCLUSION Hypocaloric diet plus orlistat in obese women is superior to diet alone with regard to the changes observed in adipokines, CRP, TNFalpha, triglycerides, IGF-1, and oxidative stress following intervention.
منابع مشابه
P-220: A Two Purpose Use of Orlistat in Obese Women with Polycystic Ovary Syndrome: Weight Loss and Androgen Reduction
Background: Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies in young women. PCOS affects 6% and 8% of women in reproductive age. Hyperandrogenism is the hallmark of PCOS. Clinically, it is possible to observe hirsutism, acne, androgenic alopecia, and signs of virilization. Laboratory examination reveals increased androgen levels. Excessive androgen has an important r...
متن کاملP-56: Effect of Metformin and Orlistat on OvulatoryStatus in Obese PCOS Patients
Background: Polycystic Ovary Syndrome (PCOS) is the commonest cause of anovulatory infertility. Treatment modes available are numerous. The use of anti-obesity medications such as orlistat or insulin sensitizing agents such as metformin is sometimes indicated in these patients. We aimed to compare the effect of metformin vs orlistat on the hormone, lipid profile &ovulation status in obese PCOS ...
متن کاملA survey on clinical effectiveness of orlistat compared to sibutramine, lorcaserin, metformin and placebo on weight loss in obese people: a network meta-analysis
Background: Trying to find a drug with more clinical efficacy in treating obesity is one of the priorities. The aim of this study was to evaluate the efficacy of orlistat, sibutramine, lorcaserin and metformin on weight loss in obese people. Methods: The databases of PubMed, Scopus, Google Scholar and Cochran Library were searched up to November 2016. In present study search strategy was perfo...
متن کاملP-148: Effect of A Low Glycemic Index Diet on Insulin Resistance and Reproductive Hormones
Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women affecting 5-10% of those of childbearing age. The majority of women with PCOS, regardless of weight, have a form of insulin resistance that is intrinsic to the syndrome. Obese women with PCOS have an added burden of insulin resistance related to their adiposity. Given the association of obesity and insuli...
متن کاملDisparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.
OBJECTIVE Polycystic ovary syndrome (PCOS) is characterized by obesity and insulin resistance (IR), which result in elevated plasminogen activator inhibitor-1 (PAI-1) levels. We aimed to assess the changes in PAI-1 levels in PCOS during treatment with metformin and during weight loss. DESIGN Twenty-three normal weight women with PCOS were given metformin 850 mg bid for 6 months. Fifty overwei...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Hormones
دوره 5 4 شماره
صفحات -
تاریخ انتشار 2006